Search Results

Intellipharmaceutics International Inc. announces its listing on NEX, a separate board of the TSX Venture Exchange.

Intellipharmaceutics International Inc. announces that, the Company has issued 1,910,000 common share purchase options pursuant to the Company’s stock option plan.

Intellipharmaceutics International Inc. announces that, it has applied and received conditional approval to list the Company’s common shares for trading on the TSX Venture Exchange as a Tier 2 Life Science Issuer.

Intellipharmaceutics International Inc. announced that its annual audited financial statements for the fiscal year ended November 30, 2023, related management’s discussion and analysis and accompanying Chief Executive Officer and Chief Financial Officer certificates and annual information form for the fiscal year ended November 30, 2023 due February 28, 2024 will not be filed by the Filing Deadline.

Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2023.

Intellipharmaceutics International Inc. today reported the results of operations for the three and six months ended May 31, 2023.

Intellipharmaceutics International Inc. reports, as required by TSX rules, that the five nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated August 1, 2023 were elected as directors of the Company at the annual meeting of shareholders of the Company.

Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and nine months ended August 31, 2022.

Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and six months ended May 31, 2022.

Intellipharmaceutics International Inc. reports, as required by TSX rules, that the five nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated April 12, 2022 were elected as directors of the Company at the annual meeting of shareholders of the Company.